Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Desoximetasone
Drug ID BADD_D00620
Description A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.
Indications and Usage For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Marketing Status approved
ATC Code D07AC03; D07XC02
DrugBank ID DB00547
KEGG ID D03697
MeSH ID D003899
PubChem ID 5311067
TTD Drug ID D0CZ1Q
NDC Product Code 45802-496; 51672-5204; 63629-8642; 68180-949; 70771-1166; 40032-024; 0168-0180; 70771-1437; 50090-5571; 51672-1270; 51672-1396; 63187-646; 71205-271; 64980-326; 51672-1261; 0472-0478; 72578-091; 0168-0151; 45802-495; 63629-8702; 68180-946; 68180-948; 0472-0479; 68180-950; 68462-531; 22552-0008; 51672-5202; 51672-5205; 51672-5281; 63629-8641; 64980-327; 72578-095; 51672-1352; 51672-5203; 53002-9280; 46439-8706; 51927-0187; 51672-1271; 51672-5263; 68180-944; 82298-112; 45802-807; 51672-1262
UNII 4E07GXB7AU
Synonyms Desoximetasone | Desoxymethasone | 17-Desoxymethasone | 17 Desoxymethasone | Deoxydexamethasone | Topicort | Stiedex | A-41304 | A 41304 | A41304 | Ibaril | Topisolon | Flubason | Topicorte | Desoxi
Chemical Information
Molecular Formula C22H29FO4
CAS Registry Number 140218-14-0
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1C(=O)CO)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mental disorder19.07.01.002--Not Available
Spinal disorder15.02.04.023--Not Available
Therapeutic reaction time decreased08.06.01.015--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Adverse drug reaction08.06.01.009--Not Available
Disease recurrence08.01.03.050--Not Available
Drug intolerance08.06.01.013--Not Available
Obstruction08.01.03.023--Not Available
Pigmentation disorder23.05.03.001--Not Available
Sinus disorder22.04.06.002--
Unevaluable event08.01.03.051--Not Available
Poor quality sleep19.02.05.005; 17.15.04.002--Not Available
Increased bronchial secretion22.12.01.002--Not Available
Increased upper airway secretion22.12.03.007--Not Available
Gastrointestinal inflammation07.08.03.007--Not Available
Infusion site extravasation12.07.05.008; 08.02.05.007--
Bronchial disorder22.03.02.009--Not Available
Treatment failure08.06.01.017--Not Available
Gastrointestinal sounds abnormal07.01.01.002--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Faeces soft07.01.03.008--Not Available
Anal incontinence17.05.01.021; 07.01.06.029--
Tachyphrenia19.10.03.010; 17.03.03.007--Not Available
Skin plaque23.03.03.044--Not Available
Sensitivity to weather change08.01.03.077--Not Available
Increased viscosity of upper respiratory secretion22.12.03.008--Not Available
Vein rupture24.03.02.032; 12.01.11.011--Not Available
Anal fissure haemorrhage24.07.02.061; 07.12.03.010--Not Available
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.002--Not Available
Electric shock sensation17.02.07.024; 08.06.02.023--Not Available
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages